ODI Medical Has New CEO and Hosts First Shareholder Meeting at the New Office

Oslo, October 27, 2021

ODI Medical announced today that Yngve Mikkelsen has been appointed the new CEO of the company. An experienced business leader, Yngve Mikkelsen, will succeed Stein Bleivik and assume responsibilities from October 1st, 2021.

ODI Medical is in a phase where a focus on product development within regulatory frameworks and a clear go-to-market strategy supported by a clear professional and commercial structure is necessary to ensure further progress. In this connection, there is a need to strengthen the competence of ODI’s top management. We would like to take this opportunity to thank Stein Bleivik for his efforts. He will be available for ODI until 2021 to ensure an effective transition.

“It was immediately clear that Yngve was the right fit,” said Tore Engebretsen, Chairman of the ODI Board. “We are excited to have Yngve as the new CEO and to lead us into a new era with his deep experience and knowledge in the medical community.”

Dr. Mikkelsen brings with him twenty years of healthcare and industry management experience in addition to more than fifteen years of experience in clinical development from pharma, biotech and MedTech.

In view of this change, ODI Medical invited shareholders to a meeting on October 27th, 2021 at the new office premises where background, status and the way forward was explained in more detail. Positive feedback from the shareholders was received after the meeting. ODI appreciates the strong support from our shareholders and will continue to strive for open communication in the journey ahead.